



April 21, 2015

The Honorable Orrin G. Hatch  
Chairman  
The Honorable Ron Wyden  
Ranking Member  
Senate Finance Committee  
U.S. Senate  
219 Dirksen Senate Office Building  
Washington, DC 20510

The Honorable Paul Ryan  
Chairman  
Committee on Ways and Means  
U.S. House of Representatives  
1102 Longworth House Office Building  
Washington, DC 20515

Dear Chairman Hatch, Ranking Member Wyden and Chairman Ryan:

On behalf of Alexion and the patients we serve globally, thank you for your leadership in introducing the Bipartisan Congressional Trade Priorities Act of 2015 (TPA). As a U.S.-based biopharmaceutical company dedicated to developing life-transforming therapies for patients who suffer from ultra-rare diseases, promoting free and fair trade based on the successful U.S. model is critical to our continued success in the global marketplace.

For Alexion, TPA sets the stage to open markets which are otherwise effectively closed to us, which in turn will allow us to serve additional patients who today may lack adequate access to potentially life-saving and transformational treatment. On far too many occasions, governments create unnecessary hurdles and impose additional costs on biopharmaceutical innovators by maintaining non-transparent regulatory and reimbursement regimes, erecting other barriers, and failing to adequately protect and account for the valuable intellectual property that serves as the very foundation of the biopharmaceutical and other industries.

We are pleased to provide our support for TPA, and appreciate your collective leadership and dedication to ensuring a competitive global playing field for companies such as Alexion as well as other U.S. innovators, job creators and workers.

Since the

A handwritten signature in black ink, appearing to read "David Hallal".

David Hallal  
Chief Executive Officer